Mogamulizumab Approved for Two Rare Types of Cutaneous T-cell Lymphoma
Mogamulizumab (Poteligeo) is indicated for  relapsed or refractory mycosis fungoides or Sézary syndrome following at least one prior systemic therapy. (Source: CancerNetwork)
Source: CancerNetwork - September 11, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

FDA Approves Poteligeo (mogamulizumab-kpkc) for Mycosis Fungoides and S ézary Syndrome
August 8, 2018 -- The U.S. Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or S ézary syndrome (SS) after... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 8, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Approves New Drug for Cutaneous T-Cell Lymphomas FDA Approves New Drug for Cutaneous T-Cell Lymphomas
The FDA has granted approval for mogamulizumab-kpkc for adult patients with relapsed or refractory mycosis fungoides or S é zary syndrome.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA approves treatment for two rare types of non-Hodgkin lymphoma
FDA approves new drug for the treatment of adults with relapsed or refractory mycosis fungoides or S ézary syndrome after at least one prior systemic therapy (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 8, 2018 Category: American Health Source Type: news

FDA approves treatment for two rare types of non-Hodgkin lymphoma
The U.S. Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. This approval provides a new treatment option for patients with MF and is the first FDA approval of a drug specifically for SS. (Source: World Pharma News)
Source: World Pharma News - August 8, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Mycosis Fungoides and Sezary Syndrome
Mycosis Fungoides and S é zary Syndrome (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 16, 2018 Category: General Medicine Source Type: news

New tool predicts deadly form of rare cancer
(Brigham and Women's Hospital) A tool to accurately determine which early-stage patients are at risk of dying from mycosis fungoides and which patients are likely to only require conventional therapy is desperately needed. Investigators from Brigham and Women's Hospital have found that next-generation, high-throughput sequencing of a specific gene (T-cell receptor beta or TCRB) is a stronger predictor of which early-stage patients will develop aggressive, progressive MF than any other established factor. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 9, 2018 Category: Cancer & Oncology Source Type: news

Cutaneous T-Cell Lymphomas: Mycosis Fungoides and S ézary Syndrome
A Guide for the Practicing OncologistThird Edition CLICK HERE TO ACCESS THE WHITE PAPER (Source: CancerNetwork)
Source: CancerNetwork - February 20, 2018 Category: Cancer & Oncology Tags: Sponsored Resources Source Type: news

Seattle Genetics Announces FDA Approval of Adcetris (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF)
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 9, 2017-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the U.S. Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) for the treatment of adult patients with primary... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 9, 2017 Category: Drugs & Pharmacology Source Type: news

EC grants marketing authorisation for Actelion ’s Ledaga to treat MF-CTCL
The European Commission (EC) has granted marketing authorisation for 160mcg of Actelion ’s Ledaga (chlormethine gel) to treat mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 8, 2017 Category: Pharmaceuticals Source Type: news

Trillium begins dosing in Phase I trial of TTI-621 for solid tumours and mycosis fungoides
Clinical stage immuno-oncology company Trillium Therapeutics has begun dosing in its second Phase I clinical trial of TTI-621 (SIRPaFc) in patients with relapsed or refractory percutaneously accessible solid tumours and mycosis fungoides. (Source: Drug Development Technology)
Source: Drug Development Technology - February 1, 2017 Category: Pharmaceuticals Source Type: news

Trillium Therapeutics Receives FDA Clearance to Proceed With TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides
TORONTO, ONTARIO--(Healthcare Sales & Marketing Network) - Trillium Therapeutics Inc. (TRIL)(TR.TO), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the US Food and Drug Administrat... Biopharmaceuticals, Oncology, FDA Trillium Therapeutics, SIRPaFc, TTI-621, mycosis fungoides (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 17, 2016 Category: Pharmaceuticals Source Type: news

Mycosis Fungoides: A Type of Skin Cancer
General information regarding Mycosis Fungoides including stages and current treatment options (Source: Disabled World)
Source: Disabled World - February 5, 2016 Category: Disability Tags: Skin Cancer & Melanoma Source Type: news

Check sweat glands, hair follicles in mycosis fungoides
SAN FRANCISCO – Check for syringotropism and folliculotropism in biopsies when managing mycosis fungoides, based on data from an ongoing observational, prospective study at Thomas Jefferson University in Philadelphia. The presence of syringotropism and folliculotropism indicates the need for more... (Source: Skin and Allergy News)
Source: Skin and Allergy News - April 22, 2015 Category: Dermatology Tags: SAN Conference News SAN Clinical News SAN News American Academy of Dermatology Source Type: news

FDA Approves Poteligeo for Rare Types of Non - Hodgkin Lymphoma
Drug approved to treat relapsed or refractory mycosis fungoides and Sézary syndrome (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Institutional, Source Type: news

Mycosis Fungoides and Leiomyosarcoma – Cancer Therapeutic Drugs and...
RnRMarketResearch.com adds “Mycosis Fungoides and Leiomyosarcoma – Pipeline Review, H2 2014” to its store. The report provides an overview of the Mycosis Fungoides and Leiomyosarcoma therapeutic...(PRWeb October 31, 2014)Read the full story at http://www.prweb.com/releases/2014-h2-retinoblastoma/leiomyosarcoma-pipeline/prweb12293087.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 1, 2014 Category: Pharmaceuticals Source Type: news

Skin Infections With Electron Beam Therapy for Mycosis...Skin Infections With Electron Beam Therapy for Mycosis...
There is a significant risk of cutaneous infection during total skin electron beam therapy (TSEBT) for mycosis fungoides, according to a new case series. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 26, 2013 Category: Consumer Health News Tags: Dermatology News Source Type: news

Non-mycosis Fungoides Cutaneous T-cell LymphomasNon-mycosis Fungoides Cutaneous T-cell Lymphomas
Primary cutaneous CD30+ T-cell lymphoproliferative disorders and their differential diagnosis are highlighted in this report from the European Society for Hematopathology. American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 19, 2013 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Mycosis Fungoides and Sézary Syndrome
The development of array comparative genomic hybridization (aCGH) techniques has allowed to characterize more precisely several human neoplasms with the aim of providing prognostic markers and targets for directed therapeutic intervention. Recently, several studies applying aCGH technique have been reported in which an exhaustive genetic characterization of mycosis fungoides (MF) and Sézary syndrome (SS) has been performed. Regarding MF, a genomic profile characterized by the gains of 7q, 17q, and 8q and losses in 9p, 13q, 17p, and 10q has been described. In SS, the most common abnormalities are gains in 8q and 17q ...
Source: Springer protocols feed by Genetics/Genomics - February 15, 2013 Category: Genetics & Stem Cells Source Type: news

Array-CGH Analysis of Cutaneous Anaplastic Large Cell Lymphoma
This chapter describes a study in which the pattern of numerical chromosomal alterations in cutaneous anaplastic large cell lymphoma (C-ALCL) tumor samples was defined using array-based comparative genomic hybridization (CGH). First, the array-based CGH technique applied is outlined in detail. Next, its application in the analysis of C-ALCL tumor specimens is described. This approach resulted in the identification of highly recurrent chromosomal alterations in C-ALCL that include gain of 7q31 and loss on 6q16-6q21 and 13q34, each affecting 45% of the patients. The pattern characteristic of C-ALCL differs markedly from chro...
Source: Springer protocols feed by Genetics/Genomics - February 15, 2013 Category: Genetics & Stem Cells Source Type: news

Classification of Mycosis Fungoides and Sezary SyndromeClassification of Mycosis Fungoides and Sezary Syndrome
This article focuses on the evaluation and classification of mycosis fungoides and Sezary syndrome, two of the most common forms of cutaneous t-cell lymphoma. What treatment options are available? Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 4, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news